Retatrutide is studied once weekly in Lilly clinical trials.
Open related pagePharmacology safety
retatrutide half life
Do not use half-life estimates from forums or seller pages to create a retatrutide dosing schedule. Retatrutide has no FDA-approved public label.
Direct answer
The safest public answer is that Lilly describes retatrutide as once weekly in clinical trials, but there is no FDA-approved retatrutide label for public-use half-life or dosing decisions.
Do not turn pharmacology estimates into self-dosing or washout plans.
Open related pageUse Lilly, FDA, and ClinicalTrials.gov for current status.
Open related pageWhat to know before acting on this search
- Half-life is only one part of dosing. Safety, tolerability, accumulation, contraindications, monitoring, and label instructions also matter.
- Once-weekly trial administration does not create a public dosing interval.
- A future approved label, if retatrutide is approved, would be the proper source for consumer pharmacology details.
- Clinical trial teams, not calculators or forums, manage study timing and safety monitoring.
Safety and compliance notes
- Self-made washout schedules can be unsafe when based on uncertain product identity or concentration.
- Counterfeit or research-use listings may not contain what the label claims.
- Half-life searches often lead into dosing content, which is not appropriate for an investigational drug.
Safer next step
Use the clinical-trial page for official study context and the dosing-schedule page for why public self-dosing guidance is not appropriate.
Medical disclaimer
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. FDA-approved medicines such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.